Should Biopharma Prepare for a Wave of Pandemic-Triggered Parkinson’s?

If you were born during the Spanish Flu of 1918, you have a 2-3 times higher risk of developing Parkinson’s. As the COVID-19 generation, are we at a similar risk? Researchers have conducted a study to answer this question. In this webinar, study author Pete Schmidt, PhD (Rho) and Mark Stacy, MD (MUSC Health) discuss the new study and what biopharma sponsors should know about its implications for future movement disorder research, including:

      • Expanding movement disorder research
      • Simplifying protocol design
      • Creating more remote evaluation opportunities
      • Operationalizing trials across non-elite centers